Session

IBD (Posters)

PRE-BIOLOGIC SCREENING IN A HIGH-RISK AREA: ARE WE ADHERING TO GUIDELINES?
PRE-BIOLOGIC SCREENING IN A HIGH-RISK AREA: ARE WE ADHERING TO GUIDELINES?

COMPARATIVE EVALUATION OF TREATMENT PERSISTENCE AND DOSE INTENSIFICATION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB
COMPARATIVE EVALUATION OF TREATMENT PERSISTENCE AND DOSE INTENSIFICATION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

TRANSLATIONAL BIOMARKERS FOR SELECTIVE, ORAL, SMALL MOLECULE ?4?7 INHIBITOR MORF-057
TRANSLATIONAL BIOMARKERS FOR SELECTIVE, ORAL, SMALL MOLECULE ?4?7 INHIBITOR MORF-057

BIOPSIES FROM ULCER EDGE YIELD HIGHER HISTOLOGICAL ACTIVITY SCORES THAN BIOPSIES NEXT TO ULCER IN ACTIVE ULCERATIVE COLITIS
BIOPSIES FROM ULCER EDGE YIELD HIGHER HISTOLOGICAL ACTIVITY SCORES THAN BIOPSIES NEXT TO ULCER IN ACTIVE ULCERATIVE COLITIS

FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNF DOSE INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS
FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNF DOSE INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS

LONG TERM USE OF BIOLOGIC AND IMMUNOMODULATORS IN INFLAMMATORY BOWEL DISEASE (IBD) AND THE RISK OF DEVELOPING CANCER: A RETROSPECTIVE REVIEW FROM A GENERAL HOSPITAL IN UNITED KINGDOM
LONG TERM USE OF BIOLOGIC AND IMMUNOMODULATORS IN INFLAMMATORY BOWEL DISEASE (IBD) AND THE RISK OF DEVELOPING CANCER: A RETROSPECTIVE REVIEW FROM A GENERAL HOSPITAL IN UNITED KINGDOM

JANUS KINASE SELECTIVITY AND THE IMPACT ON CYTOKINE SIGNALING INHIBITION AT CLINICAL RHEUMATOID ARTHRITIS DOSES
JANUS KINASE SELECTIVITY AND THE IMPACT ON CYTOKINE SIGNALING INHIBITION AT CLINICAL RHEUMATOID ARTHRITIS DOSES

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS
COMPARISON OF THE EFFECTIVENESS AND SAFETY OF THE VEDOLIZUMAB THERAPY USING IN COMBINATION WITH OR WITHOUT CYCLOSPORINE IN ULCERATIVE COLITIS

NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY
NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY

BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY
BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY

PHASE 2A PROOF OF CONCEPT PLACEBO CONTROLLED STUDY WITH ORAL ABX464 50MG QD IN ULCERATIVE COLITIS SHOWS ENDOSCOPIC IMPROVEMENT WITH LOSS OF MICROSCOPIC DISEASE ACTIVITY IN MOST ENDOSCOPIC RESPONDERS
PHASE 2A PROOF OF CONCEPT PLACEBO CONTROLLED STUDY WITH ORAL ABX464 50MG QD IN ULCERATIVE COLITIS SHOWS ENDOSCOPIC IMPROVEMENT WITH LOSS OF MICROSCOPIC DISEASE ACTIVITY IN MOST ENDOSCOPIC RESPONDERS

INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS

HIGH CORRELATION OF THE QUANTUM BLUE® RAPID ASSAY WITH HPLC TANDEM MASS SPECTROMETRY FOR INFLIXIMAB THERAPEUTIC DRUG MONITORING
HIGH CORRELATION OF THE QUANTUM BLUE® RAPID ASSAY WITH HPLC TANDEM MASS SPECTROMETRY FOR INFLIXIMAB THERAPEUTIC DRUG MONITORING

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN_S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN_S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; INTERIM ANALYSIS
PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; INTERIM ANALYSIS

MEDICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE DURING THE FIRST 12 MONTHS OF FOLLOW-UP IN PEDIATRIC, ADULT AND ELDERLY PATIENTS: A NORWEGIAN NATIONWIDE REGISTRY STUDY FROM 2009 TO 2016
MEDICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE DURING THE FIRST 12 MONTHS OF FOLLOW-UP IN PEDIATRIC, ADULT AND ELDERLY PATIENTS: A NORWEGIAN NATIONWIDE REGISTRY STUDY FROM 2009 TO 2016

IMPROVED WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MESALAZINE IN ROUTINE CLINICAL PRACTICE IN THE NETHERLANDS: RESULTS FROM THE IMPACT STUDY
IMPROVED WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MESALAZINE IN ROUTINE CLINICAL PRACTICE IN THE NETHERLANDS: RESULTS FROM THE IMPACT STUDY

SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS
SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS

IBD (Posters)  et al.

Item 261 - 280 / 558
1 2 3 4 5 6 7 8 9 10 11 12 13
14
15 16 17 18 19 20 21 22 23 24 25 26 27 28